SearcharxivSearch

arXiv subjects

Puneet Velidi

Publications and source records attributed to Puneet Velidi.

2 recordsLinked to original sources

Shape-Based Inductive Bias for Glioma Grading from Tumor Contours

Glioma grading from tumor contours is often treated as a pixel problem even when the signal of interest is shape. We align closed contours with a functional shape-alignment framework, separate global deformation from residual Fourier shape, and organize these quantities as frequency-ordered tokens. In five-fold patient-disjoint cross-validation on BraTS~2020 tumor contours, with model selection performed using grouped inner validation, a compact multilayer perceptron (MLP) achieves the highest mean balanced accuracy at 71.5\%, compared with 65.9\% for ResNet-18 and 63.3\% for ViT-Tiny. It also gives the highest mean low-grade glioma F1 at 54.9\%. Its pooled out-of-fold balanced accuracy is 72.4\% (patient-bootstrap 95\% CI: 66.4--77.8\%). The selected MLPs use 2.9k--117.3k parameters across folds, at least 46 times fewer than the pixel baselines. In a controlled noise-free simulation, shape-based models reach 56.3--71.5\% balanced accuracy while the pixel models remain at 50.0--52.5\%. This work demonstrates how incorporating a shape-based inductive bias at the representation level can improve interpretability and scalability while enabling substantial dimensionality reduction.

eess.IV

Generalized Jeffreys's approximate objective Bayes factor: Model-selection consistency, finite-sample accuracy, and statistical evidence in 71,126 clinical trial findings

Concerns about the misuse and misinterpretation of p-values and statistical significance have motivated alternatives for quantifying evidence. We define a generalized form of Jeffreys's approximate objective Bayes factor (eJAB), a one-line calculation that is a function of the p-value, sample size, and parameter dimension. We establish conditions under which eJAB is model-selection consistent and verify them for ten statistical tests. We assess finite-sample accuracy by comparing eJAB with Markov chain Monte Carlo computed Bayes factors in 12 simulation studies. We then apply eJAB to 71,126 results from ClinicalTrials.gov (CTG) and find that the proportion of findings with $\text{p-value} \le \alpha$ yet $eJAB_{01}>1$ (favoring the null) closely tracks the significance level $\alpha$, suggesting that such contradictions are pointing to the type I errors. We catalog 4,088 such candidate type I errors and provide details for 131 with reported $\text{p-value} \le 0.01$. We also identify 487 instances of the Jeffreys-Lindley paradox. Finally, we estimate that 75% (6%) of clinical trial plans from CTG set $\alpha \ge 0.05$ as the target evidence threshold, and that 35.5% (0.22%) of results significant at $\alpha =0.05$ correspond to evidence that is no stronger than anecdotal under eJAB.

stat.ME